Search results for Necitumumab ELISA Kit
Necitumumab ELISA Kit, ProteoGenix, KPTX122
Description of Necitumumab ELISA Kit Introduction Necitumumab is a monoclonal antibody that is used as a therapeutic agent for the treatment of advanced squamous non-small cell lung cancer (NSCLC). It specifically targets the epidermal growth factor receptor (EGFR), a protein that is overexpressed in many types of cancer and plays a critical role in tumor growth and progression. The development of a reliable and accurate method for measuring necitumumab levels is crucial for monitoring treatment efficacy and optimizing dosing regimens. The Necitumumab ELISA Kit provides a sensitive and specific tool for quantifying necitumumab levels in various biological samples. Structure of Necitumumab Necitumumab is a fully humanized IgG1 monoclonal antibody, meaning that it is derived from human cells and has a structure similar to that of natural human antibodies. It consists of two heavy chains and two light chains, each containing a variable region and a constant region. The variable region is responsible for binding to its target, EGFR, while the constant region determines the antibody’s effector functions. Necitumumab has a molecular weight of approximately 148 kDa and a half-life of 10-12 days in humans. Activity of Necitumumab Necitumumab exerts its therapeutic effects by binding to the extracellular domain of EGFR, preventing its activation and subsequent downstream signaling. This inhibits the proliferation and survival of cancer cells, as well as their ability to migrate and invade surrounding tissues. Additionally, necitumumab can also induce antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), which further contribute to its anti-tumor activity. Application of Necitumumab ELISA Kit The Necitumumab ELISA Kit is a highly sensitive and specific immunoassay that allows for the quantification of necitumumab levels in various biological samples, such as serum, plasma, and tissue homogenates. This kit utilizes a competitive enzyme-linked immunosorbent assay (ELISA) format, where necitumumab in the sample competes with a labeled form of the antibody for binding to a specific EGFR antigen coated on the plate. The amount of necitumumab in the sample is inversely proportional to the color intensity, which is measured using a spectrophotometer. The Necitumumab ELISA Kit has several important applications in the field of cancer research and drug development. It can be used to monitor the pharmacokinetics of necitumumab in patients undergoing treatment, as well as to assess the presence of neutralizing antibodies that may affect the drug’s efficacy. Furthermore, this kit can also be used to measure the levels of necitumumab in preclinical studies, aiding in the optimization of dosing regimens and the evaluation of potential drug interactions. Conclusion The Necitumumab ELISA Kit is a valuable tool for the accurate and reliable measurement of necitumumab levels in biological samples. Its high sensitivity and specificity make it suitable for various applications in the field of cancer research and drug development. By providing a detailed understanding of the structure, activity, and application of necitumumab, this kit contributes to the advancement of our knowledge of this important therapeutic agent and its role in the treatment of NSCLC.
Host
Reactivity
Applications
Conjugation
Necitumumab ELISA Kit, Abbexa, abx395011
Necitumumab ELISA Kit is a quantitative ELISA kit for detection of Necitumumab.Necitumumab (IMC-11F8, LY3012211) is a second-generation fully human immunoglobulin (Ig) G1 kappa isotype monoclonal antibody (mAb) that acts as an antagonist to direct against the extracellular region of epidermal growth factor receptor (EGFR). It was developed by Eli Lilly & Co (Indianapolis, IN, USA) and produced in genetically engineered mammalian NS0 cells. It was first approved by the U.S. Food and Drug Administration (FDA) under the brand name Portrazza in 2015, for use in combination with cisplatin and gemcitabine as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC). After that, it has gained the approval for marketing in the Europe Union and Japan respectively in 2016 and 2017. It is not indicated for treatment of non-squamous NSCLC. Currently, there are several ongoing clinical trials investigating necitumumab in the treatment of NSCLC in several different settings. It is currently being studied in combination with pre-existing agents, such as osimertinib, pembrolizumab, nabpaclitaxel, and carboplatin, as well as with new agents under investigation, abemaciclib and AZD9291. Necitumumab is currently being evaluated in the second-line setting following treatment failure or progression with front-line EGFR tyrosine kinase inhibitors (TKIs) and platinum-based chemotherapy.
Host
Reactivity
Human
Applications
ELISA
Conjugation
Please provide the required information below so that we can quickly source your products.